FDA records linked by MedtechLedger identify MicroPort Orthopedics, Inc. at 5677 Airline Rd., Arlington, Tennessee, as the applicant for NEXUS® Hip Stem submissions. The device is classified as a prosthesis, hip, semi-constrained, metal/ceramic/polymer, cemented or non-porous, uncemented, regulation number 888.3353, Class II, product code LZO. The company's own published product pages describe hip replacement implants and instrumentation, including the SuperPath® tissue-sparing surgical approach, and state that surgeons in over 70 countries use its hip and knee products. [1][4][5][8]
Documented hip stem filings
K250444 for the NEXUS® Hip Stem was dated February 12, 2025 and received February 14, 2025, with the FDA letter issued May 15, 2025; the record lists product codes LZO and MEH and Class II status. The later K262473 was received July 17, 2026 and decided October 1, 2026 as substantially equivalent under the special clearance pathway, with a summary statement and the orthopedic advisory committee. Both filings name Hunter Williams as the applicant contact. [4][5][1]
The 2026 submission's stated purpose is to expand compatibility with the previously 510(k) cleared NextStep Arthropedix femoral head, and the record notes that the subject NEXUS stems are compatible with previously cleared MicroPort and NextStep Arthropedix femoral heads. That scope statement describes filing coverage, not clinical performance. [7]
What the collection shows
The linked collection contains one 510(k) record, K262473, with a decision count of one substantially equivalent decision; the record sample likewise holds that single entry. These figures describe the filings assembled as of November 20, 2026 and are not a measure of total portfolio, sales or safety performance. No recall records appear in the collection. [1]
Published product and labeling material
MicroPort Orthopedics publishes an Instructions For Use viewer with downloadable PDF documents in multiple languages, alongside prescribing information. The company's hip product page describes tissue-sparing surgical hip approaches such as SuperPath®, complemented by a range of hip replacement implants and instrumentation, and cites a 2015 International Orthopaedics paper on thirty-day readmission and discharge status after hip arthroplasty using the supercapsular percutaneously-assisted total hip technique. [3][6][8]
The company's homepage states that it draws on 25 years of clinical results and lists 70 countries worldwide with distributors; the hip page separately refers to over 50 years of clinical history and to surgeons in over 70 countries using its hip and knee products. These are the manufacturer's own published statements. [9][8]
Applicant identity and boundaries
The FDA records establish MicroPort Orthopedics, Inc. as the applicant of record for these submissions, with the Arlington, Tennessee address appearing as the filing address. Corporate ownership, parent entities and brand relationships beyond the applicant name are not established by these records. The NEXUS® Hip Stem is the only device named in the linked 510(k) collection. [1][4][5]


